Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 25,416Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Genvoya

02 7Prezista/Prezcobix/Rezolsta/Symtuza

03 3Revenue share - Symtuza

04 10Stribild

05 4Symtuza

PharmaCompass

01

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
OTS 2025
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
OTS 2025
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 2,184

2019 Revenue in Millions : 2,110

Growth (%) : 4

blank

02

arrow
OTS 2025
Not Confirmed

03

arrow
OTS 2025
Not Confirmed

04

arrow
OTS 2025
Not Confirmed

05

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
OTS 2025
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
OTS 2025
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 2,083

2020 Revenue in Millions : 2,184

Growth (%) : -5

blank

06

arrow
OTS 2025
Not Confirmed

07

arrow
OTS 2025
Not Confirmed

08

arrow
OTS 2025
Not Confirmed

09

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

arrow
OTS 2025
Not Confirmed

Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

arrow
OTS 2025
Not Confirmed

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 1,943

2021 Revenue in Millions : 2,083

Growth (%) : -7

blank

10

arrow
OTS 2025
Not Confirmed